Carolina Solis-Herrera, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1952747735
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $377,995 of the $600,385 with a category attached, or 63.0%. Novo Nordisk accounts for 75.1% of it on its own, with 25 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $926.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$451K
- Bayer$93K
- Novo Nordisk AS$18K
- Boehringer Ingelheim$9K
- Boehringer Ingelheim International GmbH$8K
- Merck$4K
- plus $17K from 20 others
Across 57 payments — averaging $12,052 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$334K
- Bayer$242K
- Amgen$47K
- Lexicon Pharmaceuticals, Inc.$31K
- AstraZeneca$25K
- Novo Nordisk AS$8K
What the payments were for
- Consulting fees$107,37118%
- Speaking & faculty fees$377,99563%
- Travel & lodging$89,61615%
- Food & beverage$25,2524%
- Education$1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 412 | $451,028 |
| Bayer | 94 | $92,615 |
| Novo Nordisk AS | 6 | $18,247 |
| Boehringer Ingelheim | 19 | $9,183 |
| Boehringer Ingelheim International GmbH | 7 | $8,421 |
| Merck | 6 | $4,221 |
| Zealand Pharma US, Inc. | 7 | $4,000 |
| Mannkind Corporation | 7 | $3,799 |
| Abbott | 26 | $3,521 |
| Janssen Scientific Affairs, LLC | 11 | $1,096 |
| Lexicon Pharmaceuticals, Inc. | 5 | $742 |
| AstraZeneca | 7 | $696 |
| Corcept Therapeutics | 13 | $459 |
| Regeneron | 4 | $446 |
| Tandem Diabetes Care, Inc. | 5 | $401 |
| Pfizer | 1 | $375 |
| Dexcom, Inc. | 8 | $251 |
| Medtronic(2 entities) | 2 | $240 |
| Amarin Pharma, Inc. | 1 | $120 |
| Cequr Corporation | 1 | $108 |
| Calliditas Therapeutics US Inc. | 1 | $104 |
| Lilly USA, LLC | 1 | $89 |
| Amgen | 1 | $86 |
| Ionis Pharmaceuticals, Inc. | 1 | $72 |
| Johnson & Johnson | 1 | $46 |
| Radius Health, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$172,551
- Wegovy$105,721
- RYBELSUS$104,374
- Kerendia$89,056
- Victoza$24,524
- ZEGALOGUE$4,000
- AFREZZA$3,672
- FreeStyle Libre$2,000
- Non-Covered$993
- FREESTYLE LIBRE 3$638
- XARELTO$538
- FARXIGA$371
- FreeStyle Libre 2$258
- INVOKANA$235
- t:slim X2 Insulin Pump with Control-IQ$233
- FreeStyle Lite system$150
- EYLEA HD$150
- EYLEA$134
- CoreValve Evolut$125
- Korlym$125
How this compares
$600,385 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 138 | $228,961 |
| JardianceEmpagliflozin | 50 | $63,874 |
| MounjaroTirzepatide | 43 | $50,969 |
| FarxigaDapagliflozin Propanediol | 31 | $39,074 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $27,138 |
| KerendiaFinerenone | 13 | $23,790 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,274 |
| Novolog FlexpenInsulin Aspart | 18 | $4,948 |
| Metformin Hcl ErMetformin Hcl | 53 | $513 |
| Pioglitazone Hcl | 29 | $326 |
| Atorvastatin Calcium | 21 | $296 |
| FenofibrateFenofibrate Nanocrystallized | 11 | $266 |
| Rosuvastatin Calcium | 18 | $132 |
| Metformin Hcl | 15 | $75 |
| Lisinopril | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $451,028 | $228,961138 claims |
| Boehringer IngelheimJardiance | $9,183 | $63,87450 claims |
| Lilly USA, LLCMounjaro | $89 | $50,96943 claims |
| AstraZenecaFarxiga | $696 | $39,07431 claims |
| BayerKerendia | $92,615 | $23,79013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Ralph DefronzoSan Antonio$880K
- Firas AkhrassSan Antonio$801K
- Jeannie BaqueroSan Antonio$573K
- Kathleen HandsSan Antonio$223K
- Shahid AzizSan Antonio$173K
- William TrigosoSan Antonio$170K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.